FDA reportedly found quality-control lapses at Eli Lilly plant making COVID-19 drug

The feds found serious quality-control lapses at a New Jersey factory where Eli Lilly & Co. plans to produce its antibody treatment for COVID-19, a new report says. Food and Drug Administration officials who spent 10 days inspecting the drugmaker’s Branchburg plant last November discovered that data on the facility’s manufacturing processes had been deleted… Continue reading at New York Post